v3.25.1
Segment Reporting
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting

(14)             Segment Reporting

In accordance with FASB ASC Topic 280, Segment Reporting, the Company has determined that it operates as a single business segment, which is the development and commercialization of therapeutic and diagnostic products that service women’s reproductive health needs (infertility and permanent birth control).

The determination of a single business segment is consistent with the financial information regularly provided to the Company’s chief operating decision maker (“CODM”). As a single reportable segment entity, the Company’s segment performance measure is net loss attributable to shareholders. The measurement of segment assets is reported on the balance sheet as total assets. The Company’s CODM is its Chief Executive Officer and Chief Financial Officer, who together review and evaluate net income for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.

Significant segment expenses, as provided to the CODM are as follows:

         

        
   
Three Months Ended March 31,
   
2025
  
2024
Sales
   $ 341,264       271,140  
Cost of sales (excluding depreciation expense)
     117,266       88,532  
             
Research and development expense
     959,162       415,263  
Other research and development expenses1
     2,009,310       1,355,468  
Total research and development expense
     2,968,472       1,770,731  
             
Sales and marketing
     908,567       300,487  
General and administrative
     1,722,713       1,502,804  
Depreciation and amortization expense
     84,853       71,228  
Total operating expenses
     5,684,605       3,645,250  
             
Total other (expense) income, net
     (440,420 )     (136,868 )
Loss before income taxes
     (5,901,027 )     (3,599,510 )
Income tax (benefit)
     (4,188 )     —  
Net loss
   $ (5,896,839 )     (3,599,510 )
 
1 Other research and development expenses include clinical affairs, regulatory, manufacturing and quality assurance expenses.